Projekt

ECARA

Abgeschlossen · 2017 bis 2019

Art
Klinische Forschung
Reichweite
Multizentrisch, KSSG als teilnehmendes Zentrum
Bereiche
Status
Abgeschlossen
Start
2017
Ende
2019
Finanzierungsart
Industrie
Studiendesign
Describe lipid parameters in patients on Evolocumab at baseline and over 12 months in an observational real world setting. Maintenance of LDL-c reduction over the study period serves as surrogate for persistence with therapy and informs us about the utility of a bi-weekly or monthly SC application in clinical practice
Kurzbeschreibung/Zielsetzung

Explore Clinical Utility of Evolocumab in Combination with
an e-Health System: Swiss Prospective Observational
Study in Patients with clinical Atherosclerotic
Cardiovascular Disease (ASCVD) (ECARA)